Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 218

1.

Acceptability of lopinavir/r pellets (minitabs), tablets and syrups in HIV-infected children.

Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemant M, Nakalanzi S, Baptiste D, Walker AS, Gibb DM, Judd A.

Antivir Ther. 2016 Apr 29. doi: 10.3851/IMP3054. [Epub ahead of print]

PMID:
27128199
2.

Plasma efavirenz exposure, sex, and age predict virological response in HIV-infected African children.

Bienczak A, Denti P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H.

J Acquir Immune Defic Syndr. 2016 Apr 21. [Epub ahead of print]

PMID:
27116047
3.

Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.

Musiime V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, Mhute T, Cook A, Mugarura L, Munjoma M, Thoofer NK, Ndashimye E, Nankya I, Spyer MJ, Thomason MJ, Snowden W, Gibb DM, Walker AS; ARROW trial team.

AIDS. 2016 Apr 8. [Epub ahead of print]

PMID:
27064996
4.

Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.

Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahirya-Ntege P, Thomason M, Mugyenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team.

BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.

5.

The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.

Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P.

Br J Clin Pharmacol. 2016 Mar 16. doi: 10.1111/bcp.12934. [Epub ahead of print]

PMID:
26991336
6.

The EPIICAL project: an emerging global collaboration to investigate immunotherapeutic strategies in HIV-infected children.

Palma P, Foster C, Rojo P, Zangari P, Yates A, Cotugno N, Klein N, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Borkowsky W, Bernardi S, Calvez V, Manno E, Mora N, Compagnucci A, Wahren B, Muñoz-Fernández M, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

J Virus Erad. 2015;1(3):134-139. Epub 2015 Jun 30.

7.

Ebola vaccination.

Fitzgerald F, Yeung S, Gibb DM, Baion DE, Pollard A.

Lancet. 2015 Dec 19;386(10012):2478. doi: 10.1016/S0140-6736(15)01243-X. Epub 2015 Dec 18. No abstract available.

PMID:
26738714
8.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption.

Ananworanich J, Melvin D, Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM; PENTA 11 Study Group.

AIDS. 2016 Apr 24;30(7):1075-81. doi: 10.1097/QAD.0000000000001011.

PMID:
26730569
9.

Transfusion and Treatment of severe anaemia in African children (TRACT): a study protocol for a randomised controlled trial.

Mpoya A, Kiguli S, Olupot-Olupot P, Opoka RO, Engoru C, Mallewa M, Chimalizeni Y, Kennedy N, Kyeyune D, Wabwire B, M'baya B, Bates I, Urban B, von Hensbroek MB, Heyderman R, Thomason MJ, Uyoga S, Williams TN, Gibb DM, George EC, Walker AS, Maitland K.

Trials. 2015 Dec 29;16:593. doi: 10.1186/s13063-015-1112-4.

10.

Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.

Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D; Lablite Project Team.

BMC Health Serv Res. 2015 Nov 28;15:527. doi: 10.1186/s12913-015-1194-4.

11.

Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study.

Turkova A, Chappell E, Judd A, Goodall RL, Welch SB, Foster C, Riordan A, Shingadia D, Shackley F, Doerholt K, Gibb DM, Collins IJ; Collaborative HIV Paediatric Study (CHIPS) Steering Committee.

Lancet HIV. 2015 Dec;2(12):e530-9. doi: 10.1016/S2352-3018(15)00200-3. Epub 2015 Oct 29.

PMID:
26614967
12.

Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.

Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team.

Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.

13.

Outcomes after viral load rebound on fi rst-line antiretroviraltreatment in children with HIV in the UK and Ireland:an observational cohort study.

Childs T, Shingadia D, Goodall R, Doerholt K, Lyall H, Duong T, Judd A, Gibb DM, Collins IJ; CHIPS Steering Committee.

Lancet HIV. 2015 Apr;2(4):e151-8.

14.

The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.

Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugyenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team.

Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.

15.

Predicting mortality in sick African children: the FEAST Paediatric Emergency Triage (PET) Score.

George EC, Walker AS, Kiguli S, Olupot-Olupot P, Opoka RO, Engoru C, Akech SO, Nyeko R, Mtove G, Reyburn H, Berkley JA, Mpoya A, Levin M, Crawley J, Gibb DM, Maitland K, Babiker AG.

BMC Med. 2015 Jul 31;13:174. doi: 10.1186/s12916-015-0407-3.

16.

Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.

Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team.

AIDS. 2015 Aug 24;29(13):1623-32. doi: 10.1097/QAD.0000000000000749.

17.

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission.

Klein N, Palma P, Luzuriaga K, Pahwa S, Nastouli E, Gibb DM, Rojo P, Borkowsky W, Bernardi S, Zangari P, Calvez V, Compagnucci A, Wahren B, Foster C, Munoz-Fernández MÁ, De Rossi A, Ananworanich J, Pillay D, Giaquinto C, Rossi P.

Lancet Infect Dis. 2015 Sep;15(9):1108-14. doi: 10.1016/S1473-3099(15)00052-3. Epub 2015 Jul 14.

PMID:
26187030
18.

Reactivity of routine HIV antibody tests in children who initiated antiretroviral therapy in early infancy as part of the Children with HIV Early Antiretroviral Therapy (CHER) trial: a retrospective analysis.

Payne H, Mkhize N, Otwombe K, Lewis J, Panchia R, Callard R, Morris L, Babiker A, Violari A, Cotton MF, Klein NJ, Gibb DM.

Lancet Infect Dis. 2015 Jul;15(7):803-9. doi: 10.1016/S1473-3099(15)00087-0. Epub 2015 Jun 1.

19.

Corrections. The expanding role of co-trimoxazole in developing countries.

Church JA, Fitzgerald F, Walker AS, Gibb DM.

Lancet Infect Dis. 2015 Mar;15(3):263. doi: 10.1016/S1473-3099(14)71012-6. Epub 2015 Jan 22. No abstract available.

PMID:
25749219
20.

Pubertal development in HIV-infected African children on first-line antiretroviral therapy.

Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team.

AIDS. 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk